

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSSPTA1642BJF

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

\* \* \* \* \* Welcome to STN International \* \* \* \* \*

NEWS 1 Web Page URLs for STN Seminar Schedule - N. America  
NEWS 2 "Ask CAS" for self-help around the clock  
NEWS 3 SEP 01 New pricing for the Save Answers for SciFinder Wizard within  
STN Express with Discover!  
NEWS 4 OCT 28 KOREAPAT now available on STN  
NEWS 5 NOV 30 PHAR reloaded with additional data  
NEWS 6 DEC 01 LISA now available on STN  
NEWS 7 DEC 09 12 databases to be removed from STN on December 31, 2004  
NEWS 8 DEC 15 MEDLINE update schedule for December 2004  
NEWS 9 DEC 17 ELCOM reloaded; updating to resume; current-awareness  
alerts (SDIs) affected  
NEWS 10 DEC 17 COMPUAB reloaded; updating to resume; current-awareness  
alerts (SDIs) affected  
NEWS 11 DEC 17 SOLIDSTATE reloaded; updating to resume; current-awareness  
alerts (SDIs) affected  
NEWS 12 DEC 17 CERAB reloaded; updating to resume; current-awareness  
alerts (SDIs) affected  
NEWS 13 DEC 17 THREE NEW FIELDS ADDED TO IFIPAT/IFIUDB/IFICDB  
NEWS 14 DEC 30 EPFULL: New patent full text database to be available on STN  
NEWS 15 DEC 30 CAPLUS - PATENT COVERAGE EXPANDED  
NEWS 16 JAN 03 No connect-hour charges in EPFULL during January and  
February 2005  
NEWS 17 FEB 25 CA/CAPLUS - Russian Agency for Patents and Trademarks  
(ROSPATENT) added to list of core patent offices covered  
NEWS 18 FEB 10 STN Patent Forums to be held in March 2005  
NEWS 19 FEB 16 STN User Update to be held in conjunction with the 229th ACS  
National Meeting on March 13, 2005  
NEWS 20 FEB 28 PATDPAFULL - New display fields provide for legal status  
data from INPADOC  
NEWS 21 FEB 28 BABS - Current-awareness alerts (SDIs) available  
NEWS 22 FEB 28 MEDLINE/LMEDLINE reloaded  
NEWS 23 MAR 02 GBFULL: New full-text patent database on STN  
NEWS 24 MAR 03 REGISTRY/ZREGISTRY - Sequence annotations enhanced  
NEWS 25 MAR 03 MEDLINE file segment of TOXCENTER reloaded  
NEWS 26 MAR 22 KOREAPAT now updated monthly; patent information enhanced  
NEWS 27 MAR 22 Original IDE display format returns to REGISTRY/ZREGISTRY  
NEWS 28 MAR 22 PATDPASPC - New patent database available  
NEWS 29 MAR 22 REGISTRY/ZREGISTRY enhanced with experimental property tags  
  
NEWS EXPRESS JANUARY 10 CURRENT WINDOWS VERSION IS V7.01a, CURRENT  
MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP),  
AND CURRENT DISCOVER FILE IS DATED 10 JANUARY 2005  
  
NEWS HOURS STN Operating Hours Plus Help Desk Availability  
NEWS INTER General Internet Information  
NEWS LOGIN Welcome Banner and News Items  
NEWS PHONE Direct Dial and Telecommunication Network Access to STN  
NEWS WWW CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

\* \* \* \* \* STN Columbus \* \* \* \* \*

FILE 'HOME' ENTERED AT 10:35:18 ON 25 MAR 2005

=> file reg

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

0.21

0.21

FILE 'REGISTRY' ENTERED AT 10:35:27 ON 25 MAR 2005

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2005 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 24 MAR 2005 HIGHEST RN 847222-24-6

DICTIONARY FILE UPDATES: 24 MAR 2005 HIGHEST RN 847222-24-6

TSCA INFORMATION NOW CURRENT THROUGH JANUARY 18, 2005

Please note that search-term pricing does apply when conducting SmartSELECT searches.

\*\*\*\*\*  
\*  
\* The CA roles and document type information have been removed from \*  
\* the IDE default display format and the ED field has been added, \*  
\* effective March 20, 2005. A new display format, IDERL, is now \*  
\* available and contains the CA role and document type information. \*  
\*  
\*\*\*\*\*

Crossover limits have been increased. See HELP CROSSOVER for details.

Experimental and calculated property data are now available. For more information enter HELP PROP at an arrow prompt in the file or refer to the file summary sheet on the web at:

<http://www.cas.org/ONLINE/DBSS/registryss.html>

=> E "CANGLUSTRATIDE"/CN 25

E1	1	CANFOSFAMIDE/CN
E2	1	CANGITOXIN (REDUCED)/CN
E3	0 -->	CANGLUSTRATIDE/CN
E4	1	CANGLUSTRATIDE HYDROCHLORIDE/CN
E5	1	CANGORIN A/CN
E6	1	CANGORIN B/CN
E7	1	CANGORIN C/CN
E8	1	CANGORIN D/CN
E9	1	CANGORIN E/CN
E10	1	CANGORIN F/CN
E11	1	CANGORIN G/CN
E12	1	CANGORIN H/CN
E13	1	CANGORIN I/CN
E14	1	CANGORIN J/CN

E15 1 CANGORINE A/CN  
E16 1 CANGORINE B/CN  
E17 1 CANGORINE C/CN  
E18 1 CANGORINE D/CN  
E19 1 CANGORINE E/CN  
E20 1 CANGORINE F/CN  
E21 1 CANGORINE G/CN  
E22 1 CANGORINE G 10-ACETATE/CN  
E23 1 CANGORINE H/CN  
E24 1 CANGORINE I/CN  
E25 1 CANGORINE J/CN

=> S E4

L1 1 "CANGLUSTRATIDE HYDROCHLORIDE"/CN

=> DIS L1 1 SQIDE

THE ESTIMATED COST FOR THIS REQUEST IS 6.15 U.S. DOLLARS  
DO YOU WANT TO CONTINUE WITH THIS REQUEST? (Y)/N:Y

L1 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2005 ACS on STN

RN 439943-59-6 REGISTRY

CN Glycine, L- $\gamma$ -glutamyl-3-[[2-[[bis[bis(2-chloroethyl)amino]phosphinyl]oxy]ethyl]sulfonyl]-L-alanyl-2-phenyl-, monohydrochloride, (2R)- (9CI) (CA INDEX NAME)

OTHER NAMES:

CN Canglustratide hydrochloride

CN TER 286

CN TLK 286

FS STEREOSEARCH

MF C26 H40 Cl4 N5 O10 P S . Cl H

SR CAS Client Services

LC STN Files: ADISINSIGHT, CA, CAPLUS, PHAR, PROUSDDR, SYNTHLINE, TOXCENTER, USPATFULL

DT.CA Cplus document type: Conference; Journal; Patent

RL.P Roles from patents: BIOL (Biological study); USES (Uses)

RLD.P Roles for non-specific derivatives from patents: BIOL (Biological study); USES (Uses)

RL.NP Roles from non-patents: BIOL (Biological study); PROC (Process); USES (Uses)

CRN (158382-37-7)

Absolute stereochemistry.

/ Structure 1 in file .gra /

18 REFERENCES IN FILE CA (1907 TO DATE)

1 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA

18 REFERENCES IN FILE CAPLUS (1907 TO DATE)

=> file medline

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

6.87

7.08

FILE 'MEDLINE' ENTERED AT 10:36:18 ON 25 MAR 2005

FILE LAST UPDATED: 24 MAR 2005 (20050324/UP). FILE COVERS 1950 TO DATE.

On December 19, 2004, the 2005 MeSH terms were loaded.

The MEDLINE reload for 2005 is now available. For details enter HELP RLOAD at an arrow prompt (=>). See also:

<http://www.nlm.nih.gov/mesh/>  
[http://www.nlm.nih.gov/pubs/techbull/nd04/nd04\\_mesh.html](http://www.nlm.nih.gov/pubs/techbull/nd04/nd04_mesh.html)

OLDMEDLINE now back to 1950.

MEDLINE thesauri in the /CN, /CT, and /MN fields incorporate the MeSH 2005 vocabulary.

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> s 11

L2 0 L1

=> file caplus

COST IN U.S. DOLLARS

SINCE FILE

ENTRY

TOTAL

SESSION

FULL ESTIMATED COST

0.40

7.48

FILE 'CAPLUS' ENTERED AT 10:36:25 ON 25 MAR 2005

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2005 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 25 Mar 2005 VOL 142 ISS 14

FILE LAST UPDATED: 24 Mar 2005 (20050324/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> s 11

L3 18 L1

=> s 13 and (cancer? or tumor? or neoplas?)

253494 CANCER?

384869 TUMOR?

402446 NEOPLAS?

L4 18 L3 AND (CANCER? OR TUMOR? OR NEOPLAS?)

=> s 14 not py>2002

2461177 PY>2002

L5 8 L4 NOT PY>2002

=> d ibib 1-4

L5 ANSWER 1 OF 8 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2003:61250 CAPLUS

DOCUMENT NUMBER: 139:143479

TITLE: Efficacy of a glutathione S-transferase  $\pi$ -activated prodrug in platinum-resistant ovarian cancer cells

AUTHOR(S): Townsend, Danyelle M.; Shen, Hongxie; Staros,

CORPORATE SOURCE: Alexandra L.; Gate, Laurent; Tew, Kenneth D.  
Department of Pharmacology, Fox Chase Cancer Center,  
Philadelphia, PA, 19111, USA  
SOURCE: Molecular Cancer Therapeutics (2002), 1(12), 1089-1095  
CODEN: MCTOCF; ISSN: 1535-7163  
PUBLISHER: American Association for Cancer Research  
DOCUMENT TYPE: Journal  
LANGUAGE: English  
REFERENCE COUNT: 24 THERE ARE 24 CITED REFERENCES AVAILABLE FOR THIS  
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 2 OF 8 CAPLUS COPYRIGHT 2005 ACS on STN  
ACCESSION NUMBER: 2001:316848 CAPLUS  
DOCUMENT NUMBER: 135:116763  
TITLE: The influence of GST-targeted drugs on cell  
proliferation and stress response  
AUTHOR(S): Tew, Kenneth D.  
CORPORATE SOURCE: Department of Pharmacology, Fox Chase Cancer Center,  
Philadelphia, PA, USA  
SOURCE: Chemico-Biological Interactions (2001), 133(1-3),  
295-300  
CODEN: CBINA8; ISSN: 0009-2797  
PUBLISHER: Elsevier Science Ireland Ltd.  
DOCUMENT TYPE: Journal  
LANGUAGE: English  
REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS  
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 3 OF 8 CAPLUS COPYRIGHT 2005 ACS on STN  
ACCESSION NUMBER: 2000:466901 CAPLUS  
DOCUMENT NUMBER: 133:171845  
TITLE: Cellular response to a glutathione S-transferase P1-1  
activated prodrug  
AUTHOR(S): Rosario, Lilliam A.; O'Brien, Miechelle L.; Henderson,  
Colin J.; Wolf, C. Roland; Tew, Kenneth D.  
CORPORATE SOURCE: Department of Pharmacology, Fox Chase Cancer Center,  
Philadelphia, PA, USA  
SOURCE: Molecular Pharmacology (2000), 58(1), 167-174  
CODEN: MOPMA3; ISSN: 0026-895X  
PUBLISHER: American Society for Pharmacology and Experimental  
Therapeutics  
DOCUMENT TYPE: Journal  
LANGUAGE: English  
REFERENCE COUNT: 28 THERE ARE 28 CITED REFERENCES AVAILABLE FOR THIS  
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 4 OF 8 CAPLUS COPYRIGHT 2005 ACS on STN  
ACCESSION NUMBER: 1998:402062 CAPLUS  
DOCUMENT NUMBER: 129:117526  
TITLE: Tumor efficacy and bone marrow-sparing  
properties of TER286, a cytotoxin activated by  
glutathione S-transferase  
AUTHOR(S): Morgan, Amy S.; Sanderson, Polly E.; Borch, Richard  
F.; Tew, Kenneth D.; Niitsu, Yoshiro; Takayama,  
Tetsuji; Von Hoff, Daniel D.; Izbicka, Elzbieta;  
Mangold, Gina; Paul, Christer; Broberg, Ulrika;  
Mannervik, Bengt; Henner, W. David; Kauvar, Lawrence  
M.  
CORPORATE SOURCE: Terrapin Technologies, Inc., South San Francisco, CA,  
94080, USA  
SOURCE: Cancer Research (1998), 58(12), 2568-2575  
CODEN: CNREA8; ISSN: 0008-5472  
PUBLISHER: American Association for Cancer Research  
DOCUMENT TYPE: Journal  
LANGUAGE: English

REFERENCE COUNT: 59 THERE ARE 59 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> d 5-8

L5 ANSWER 5 OF 8 CAPLUS COPYRIGHT 2005 ACS on STN  
AN 1997:348755 CAPLUS  
DN 127:60274  
TI Activity of TER286 against human tumor colony-forming units  
AU Izbicka, Elzbieta; Lawrence, Richard; Cerna, Caesar; Von Hoff, Daniel D.; Sanderson, Polly E.  
CS Inst. Drug Development, Cancer Therapy Res. Center, San Antonio, TX, 78245, USA  
SO Anti-Cancer Drugs (1997), 8(4), 345-348  
CODEN: ANTDEV; ISSN: 0959-4973  
PB Rapid Science Publishers  
DT Journal  
LA English  
RE.CNT 17 THERE ARE 17 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 6 OF 8 CAPLUS COPYRIGHT 2005 ACS on STN  
AN 1996:695835 CAPLUS  
DN 126:554  
TI Glutathione-based anti-cancer drugs: Animal efficacy and bone marrow sparing effects  
AU Lyttle, M. H.; Satyam, A.; Hocker, M. D.; Hui, H. C.; Caldwell, C. G.; Morgan, A. S.; Stanboli, A.; Kauvar, L. M.  
CS Terrapin Technologies, South San Francisco, CA, 94080, USA  
SO Peptides: Chemistry, Structure and Biology, Proceedings of the American Peptide Symposium, 14th, Columbus, Ohio, June 18-23, 1995 (1996), Meeting Date 1995, 170-171. Editor(s): Kaumaya, Pravin T. P.; Hodges, Robert S. Publisher: Mayflower Scientific, Kingswinford, UK.  
CODEN: 63NTAF  
DT Conference  
LA English

L5 ANSWER 7 OF 8 CAPLUS COPYRIGHT 2005 ACS on STN  
AN 1996:175896 CAPLUS  
DN 124:278186  
TI Design, Synthesis, and Evaluation of Latent Alkylating Agents Activated by Glutathione S-Transferase  
AU Satyam, Apparao; Hocker, Michael D.; Kane-Maguire, Kim A.; Morgan, Amy S.; Villar, Hugo O.; Lyttle, Matthew H.  
CS Terrapin Technologies Inc., South San Francisco, CA, 94080, USA  
SO Journal of Medicinal Chemistry (1996), 39(8), 1736-47  
CODEN: JMCMAR; ISSN: 0022-2623  
PB American Chemical Society  
DT Journal  
LA English

L5 ANSWER 8 OF 8 CAPLUS COPYRIGHT 2005 ACS on STN  
AN 1995:892014 CAPLUS  
DN 124:21231  
TI Modulation of detoxification gene expression in human colon HT29 cells by glutathione-S-transferase inhibitors  
AU Ciaccio, Paul J.; Shen, Hongxie; Jaiswal, Anil K.; Lyttle, Matthew H.; Tew, Kenneth D.  
CS Dep. Pharmacol., Fox Chase Cancer Cent., Philadelphia, PA, 19111, USA  
SO Molecular Pharmacology (1995), 48(4), 639-47  
CODEN: MOPMA3; ISSN: 0026-895X  
PB Williams & Wilkins  
DT Journal  
LA English

=> file pctfull  
COST IN U.S. DOLLARS  
FULL ESTIMATED COST

SINCE FILE	TOTAL
ENTRY	SESSION
17.71	25.19

FILE 'PCTFULL' ENTERED AT 10:38:07 ON 25 MAR 2005  
COPYRIGHT (C) 2005 Univention

FILE LAST UPDATED: 23 MAR 2005 <20050323/UP>  
MOST RECENT UPDATE WEEK: 200511 <200511/EW>  
FILE COVERS 1978 TO DATE

>>> IMAGES ARE AVAILABLE ONLINE AND FOR EMAIL-PRINTS <<<

=> s l1  
'CN' IS NOT A VALID FIELD CODE  
L6 0 "CANGLUSTRATIDE HYDROCHLORIDE"/CN

=> s canglustratide  
L7 1 CANGLUSTRATIDE

=>

---Logging off of STN---

=>  
Executing the logoff script...

=> LOG Y

COST IN U.S. DOLLARS	SINCE FILE	TOTAL
FULL ESTIMATED COST	ENTRY	SESSION
	1.05	26.24

STN INTERNATIONAL LOGOFF AT 10:38:43 ON 25 MAR 2005

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSSPTA1642BJF

PASSWORD:  
TERMINAL (ENTER 1, 2, 3, OR ?):2

\* \* \* \* \* Welcome to STN International \* \* \* \* \*

NEWS	1	Web Page URLs for STN Seminar Schedule - N. America
NEWS	2	"Ask CAS" for self-help around the clock
NEWS	3 FEB 27	New STN AnaVist pricing effective March 1, 2006
NEWS	4 APR 04	STN AnaVist \$500 visualization usage credit offered
NEWS	5 MAY 10	CA/CAPLUS enhanced with 1900-1906 U.S. patent records
NEWS	6 MAY 11	KOREAPAT updates resume
NEWS	7 MAY 19	Derwent World Patents Index to be reloaded and enhanced

NEWS 8 MAY 30 IPC 8 Rolled-up Core codes added to CA/Caplus and  
USPATFULL/USPAT2  
NEWS 9 MAY 30 The F-Term thesaurus is now available in CA/Caplus  
NEWS 10 JUN 02 The first reclassification of IPC codes now complete in  
INPADOC  
NEWS 11 JUN 26 TULSA/TULSA2 reloaded and enhanced with new search and  
and display fields  
NEWS 12 JUN 28 Price changes in full-text patent databases EPFULL and PCTFULL  
NEWS 13 JUL 11 CHEMSAFE reloaded and enhanced  
NEWS 14 JUL 14 FSTA enhanced with Japanese patents  
NEWS 15 JUL 19 Coverage of Research Disclosure reinstated in DWPI  
NEWS 16 AUG 09 INSPEC enhanced with 1898-1968 archive

NEWS EXPRESS JUNE 30 CURRENT WINDOWS VERSION IS V8.01b, CURRENT  
MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP),  
AND CURRENT DISCOVER FILE IS DATED 26 JUNE 2006.

NEWS HOURS STN Operating Hours Plus Help Desk Availability  
NEWS LOGIN Welcome Banner and News Items  
NEWS IPC8 For general information regarding STN implementation of IPC 8  
NEWS X25 X.25 communication option no longer available

Enter NEWS followed by the item number or name to see news on that  
specific topic.

All use of STN is subject to the provisions of the STN Customer  
agreement. Please note that this agreement limits use to scientific  
research. Use for software development or design or implementation  
of commercial gateways or other similar uses is prohibited and may  
result in loss of user privileges and other penalties.

\* \* \* \* \* STN Columbus \* \* \* \* \*

FILE 'HOME' ENTERED AT 09:33:34 ON 14 AUG 2006

=> file caplus  
COST IN U.S. DOLLARS

SINCE FILE	TOTAL
ENTRY	SESSION
0.21	0.21

FULL ESTIMATED COST

FILE 'CAPLUS' ENTERED AT 09:33:41 ON 14 AUG 2006

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is  
held by the publishers listed in the PUBLISHER (PB) field (available  
for records published or updated in Chemical Abstracts after December  
26, 1996), unless otherwise indicated in the original publications.  
The CA Lexicon is the copyrighted intellectual property of the  
American Chemical Society and is provided to assist you in searching  
databases on STN. Any dissemination, distribution, copying, or storing  
of this information, without the prior written consent of CAS, is  
strictly prohibited.

FILE COVERS 1907 - 14 Aug 2006 VOL 145 ISS 8  
FILE LAST UPDATED: 13 Aug 2006 (20060813/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply.  
They are available for your review at:

<http://www.cas.org/infopolicy.html>

=> s 439943-59-6/rn



31 439943-59-6  
2 439943-59-6D  
L1 29 439943-59-6/RN  
(439943-59-6 (NOTL) 439943-59-6D )

=> s carboplatin/cn  
REGISTRY INITIATED

Substance data SEARCH and crossover from CAS REGISTRY in progress...  
Use DISPLAY HITSTR (or FHITSTR) to directly view retrieved structures.

L3 4320 L2

=> s 11 and 13

L4 11 L1 AND L3

=> d ibib 1-11

L4 ANSWER 1 OF 11 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2006:167588 CAPLUS

DOCUMENT NUMBER: 144:254148

TITLE: Aminopteridinones as anticancer agents, their  
preparation, pharmaceutical compositions, and use in  
therapy

INVENTOR(S): Munzert, Gerd; Steegmaier, Martin; Baum, Anke

PATENT ASSIGNEE(S): Boehringer Ingelheim International G.m.b.H., Germany;  
Boehringer Ingelheim Pharma G.m.b.H. & Co. K.-G.

SOURCE: PCT Int. Appl., 158 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006018182	A1	20060223	WO 2005-EP8623	20050809
WO 2006018182	C1	20060608		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,  
CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,  
GE, GH, GM, GR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ,  
LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA,  
NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK,  
SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU,  
ZA, ZM, ZW

RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE,  
IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ,  
CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH,  
GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,  
KG, KZ, MD, RU, TJ, TM

US 2006058311 A1 20060316 US 2005-189540 20050726

PRIORITY APPLN. INFO.: EP 2004-19361 A 20040814

EP 2004-19448 A 20040817

OTHER SOURCE(S): MARPAT 144:254148

REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS  
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 2 OF 11 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2005:1290072 CAPLUS

DOCUMENT NUMBER: 144:46998

TITLE: The X-ray crystal structure of BRCA1 tandem BRCT repeat and BACH1 phosphopeptide complex and methods and compositions for antitumor drug design

INVENTOR(S): Yaffe, Michael B.; Clapperton, Julie A.; Manke, Isaac A.; Lowery, Drew M.; Ho, Timmy; Haire, Lesley F.; Smerdon, Stephen J.

PATENT ASSIGNEE(S): Massachusetts Institute of Technology, USA

SOURCE: PCT Int. Appl., 360 pp.  
CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005115454	A2	20051208	WO 2005-US15981	20050509
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				

PRIORITY APPLN. INFO.: US 2004-569131P P 20040507

L4 ANSWER 3 OF 11 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2005:1242685 CAPLUS

DOCUMENT NUMBER: 143:472533

TITLE: GST-activated anticancer therapy for sensitization or side effect amelioration of another anticancer

INVENTOR(S): Brown, Gail L.; Keck, James G.; Wick, Michael M.

PATENT ASSIGNEE(S): USA

SOURCE: U.S. Pat. Appl. Publ., 13 pp.  
CODEN: USXXCO

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2005261202	A1	20051124	US 2005-133833	20050519
WO 2005112973	A1	20051201	WO 2005-US17960	20050519
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				

PRIORITY APPLN. INFO.: US 2004-572790P P 20040520

OTHER SOURCE(S): MARPAT 143:472533

L4 ANSWER 4 OF 11 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2005:1239173 CAPLUS  
 DOCUMENT NUMBER: 143:477963  
 TITLE: Preparation of pyrazolyl urea derivatives as TrkA kinase inhibitors useful in the treatment of cancer  
 INVENTOR(S): Lee, Wendy; Ladouceur, Gaetan; Dumas, Jacques; Smith, Roger; Ying, Shihong; Wang, Gan; Chen, Zhi; Liu, Qingjie; Mokdad, Holia Hatoum  
 PATENT ASSIGNEE(S): Bayer Pharmaceuticals Corporation, USA  
 SOURCE: PCT Int. Appl., 215 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005110994	A2	20051124	WO 2005-US15106	20050502
WO 2005110994	A3	20060202		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			

PRIORITY APPLN. INFO.: US 2004-566445P P 20040430  
 OTHER SOURCE(S): MARPAT 143:477963

L4 ANSWER 5 OF 11 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2005:409543 CAPLUS  
 DOCUMENT NUMBER: 142:457053  
 TITLE: Human protein IAP (inhibitor of apoptosis protein) nucleobase oligomers, including dsRNA, shRNA, and siRNA, and their use for enhancing apoptosis in cancer therapy  
 INVENTOR(S): Lacasse, Eric; McManus, Daniel  
 PATENT ASSIGNEE(S): Aegera Therapeutics, Inc., Can.  
 SOURCE: PCT Int. Appl., 112 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005042558	A1	20050512	WO 2004-CA1902	20041029
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
US 2005148535	A1	20050707	US 2004-975974	20041028

CA 2542904 AA 20050512 CA 2004-2542904 20041029  
 EP 1682565 A1 20060726 EP 2004-789809 20041029  
 R: DE, FR, GB  
 PRIORITY APPLN. INFO.: US 2003-516192P P 20031030  
 WO 2004-CA1902 W 20041029

L4 ANSWER 6 OF 11 CAPLUS COPYRIGHT 2006 ACS on STN  
 ACCESSION NUMBER: 2005:409357 CAPLUS  
 DOCUMENT NUMBER: 142:457052  
 TITLE: Sequences of antisense IAP (inhibitor of apoptosis protein) oligomers and their use for treatment of proliferative diseases with a chemotherapeutic agent  
 INVENTOR(S): Lacasse, Eric; McManus, Daniel; Durkin, Jon P.  
 PATENT ASSIGNEE(S): Aegea Therapeutics, Inc., Can.  
 SOURCE: PCT Int. Appl., 285 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005042030	A1	20050512	WO 2004-CA1900	20041029
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 2005119217	A1	20050602	US 2004-975790	20041028
AU 2004284855	A1	20050512	AU 2004-284855	20041029
CA 2542884	AA	20050512	CA 2004-2542884	20041029
PRIORITY APPLN. INFO.:		US 2003-516263P P 20031030 WO 2004-CA1900 W 20041029		
REFERENCE COUNT:		6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT		

L4 ANSWER 7 OF 11 CAPLUS COPYRIGHT 2006 ACS on STN  
 ACCESSION NUMBER: 2005:283298 CAPLUS  
 DOCUMENT NUMBER: 142:349042  
 TITLE: Combinations of chlorpromazine compounds and antiproliferative drugs for the treatment of neoplasms  
 INVENTOR(S): Lée, Margaret S.; Nichols, James M.; Zhang, Yanzhen; Keith, Curtis  
 PATENT ASSIGNEE(S): Combinatorx, Incorporated, USA  
 SOURCE: PCT Int. Appl., 65 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 7  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005027842	A2	20050331	WO 2004-US30368	20040916
WO 2005027842	A3	20051222		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,				

LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI,  
 NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY,  
 TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW  
 RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM,  
 AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK,  
 EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE,  
 SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE,  
 SN, TD, TG

AU 2004273910 A1 20050331 AU 2004-273910 20040916  
 CA 2538570 AA 20050331 CA 2004-2538570 20040916  
 EP 1670477 A2 20060621 EP 2004-788798 20040916

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,  
 IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR

PRIORITY APPLN. INFO.: US 2003-504310P P 20030918  
 WO 2004-US30368 W 20040916

OTHER SOURCE(S): MARPAT 142:349042

L4 ANSWER 8 OF 11 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2005:158629 CAPLUS

DOCUMENT NUMBER: 142:246160

TITLE: Treatment of lung cancer with vitamin D compounds in  
 combination with other treatments

INVENTOR(S): Henner, William D.

PATENT ASSIGNEE(S): Novacea, Inc., USA

SOURCE: PCT Int. Appl., 55 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 2

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005016872	A1	20050224	WO 2004-US18427	20040610
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				

AU 2004265238 A1 20050224 AU 2004-265238 20040610  
 CA 2528519 AA 20050224 CA 2004-2528519 20040610  
 EP 1631543 A1 20060308 EP 2004-776421 20040610

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,  
 IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK

CN 1802349 A 20060712 CN 2004-80015998 20040610  
 US 2006172014 A1 20060803 US 2005-298927 20051212

PRIORITY APPLN. INFO.: US 2003-477339P P 20030611  
 US 2004-569245P P 20040510  
 WO 2004-US18427 W 20040610

REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS  
 RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 9 OF 11 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2004:965067 CAPLUS

DOCUMENT NUMBER: 141:406039

TITLE: Combinations for the treatment of diseases involving  
 cell proliferation, migration or apoptosis of myeloma  
 cells, or angiogenesis

INVENTOR(S): Hilberg, Frank; Solca, Flavio; Stefanic, Martin

Friedrich; Baum, Anke; Munzert, Gerd; Van Meel,  
 Jacobus C. A.  
 PATENT ASSIGNEE(S): Boehringer Ingelheim International G.m.b.H., Germany;  
 Boehringer Ingelheim Pharma G.m.b.H. & Co. K.-G.  
 SOURCE: PCT Int. Appl., 101 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 2  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004096224	A2	20041111	WO 2004-EP4363	20040424
WO 2004096224	A3	20041216		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
EP 1473043	A1	20041103	EP 2003-9587	20030429
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
AU 2004233576	A1	20041111	AU 2004-233576	20040424
CA 2523868	AA	20041111	CA 2004-2523868	20040424
EP 1622619	A2	20060208	EP 2004-729366	20040424
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK				
BR 2004009919	A	20060425	BR 2004-9919	20040424
NO 2005005605	A	20051128	NO 2005-5605	20051128
PRIORITY APPLN. INFO.:				
			EP 2003-9587	A 20030429
			EP 2004-508	A 20040113
			EP 2004-1171	A 20040121
			WO 2004-EP4363	W 20040424

L4 ANSWER 10 OF 11 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2004:756710 CAPLUS  
 DOCUMENT NUMBER: 141:277628  
 TITLE: Preparation of ureidophenoxycyanopyridines as  
 anticancer drugs.  
 INVENTOR(S): Scott, William J.; Dumas, Jacques; Boyer, Stephen;  
 Lee, Wendy; Chen, Yuanwei; Phillips, Barton; Verma,  
 Sharad; Chen, Jianqing; Chen, Zhi; Fan, Jianmei;  
 Raudenbush, Brian; Redman, Aniko; Yi, Lin; Zhu,  
 Qingming  
 PATENT ASSIGNEE(S): Bayer Pharmaceuticals Corporation, USA  
 SOURCE: PCT Int. Appl., 127 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 4  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004078747	A1	20040916	WO 2004-US6286	20040301
WO 2004078747	C1	20041104		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,				

GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,  
 LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI  
 RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE,  
 BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU,  
 MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA,  
 GN, GQ, GW, ML, MR, NE, SN, TD, TG

US 2004235829	A1	20041125	US 2004-788029	20040227
AU 2004217977	A1	20040916	AU 2004-217977	20040301
CA 2517361	AA	20040916	CA 2004-2517361	20040301
US 2004229937	A1	20041118	US 2004-789446	20040301
US 2005032798	A1	20050210	US 2004-788405	20040301
US 2005038031	A1	20050217	US 2004-788426	20040301
EP 1599467	A1	20051130	EP 2004-716144	20040301

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,  
 IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK

BR 2004007897	A	20060301	BR 2004-7897	20040301
---------------	---	----------	--------------	----------

PRIORITY APPLN. INFO.:

US 2003-450323P	P	20030228
US 2003-450324P	P	20030228
US 2003-450348P	P	20030228
WO 2004-US6286	A	20040301

OTHER SOURCE(S): MARPAT 141:277628  
 REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS  
 RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 11 OF 11 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2004:453016 CAPLUS

DOCUMENT NUMBER: 141:1227

TITLE: Combination cancer therapy with a glutathione  
 S-transferase (GST)-activated anticancer compound and  
 another anticancer therapy

INVENTOR(S): Xu, Hua; Brown, Gail L.; Schow, Steven R.; Keck, James  
 G.

PATENT ASSIGNEE(S): Telik, Inc., USA

SOURCE: PCT Int. Appl., 38 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004045593	A2	20040603	WO 2003-US36209	20031114
WO 2004045593	A3	20040812		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,			
	CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,			
	GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,			
	LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO,			
	NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ,			
	TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ,			
	BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE,			
	ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK,			
	TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
CA 2505377	AA	20040603	CA 2003-2505377	20031114
AU 2003290805	A1	20040615	AU 2003-290805	20031114
US 2004138140	A1	20040715	US 2003-714593	20031114
EP 1562564	A2	20050817	EP 2003-783388	20031114
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,			
	IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK			
BR 2003016364	A	20051004	BR 2003-16364	20031114
CN 1711076	A	20051221	CN 2003-80103404	20031114
JP 2006508980	T2	20060316	JP 2004-553614	20031114

PRIORITY APPLN. INFO.:

US 2002-426983P	P	20021115
WO 2003-US36209	W	20031114

OTHER SOURCE(S): MARPAT 141:1227

=> s combinatination

0 COMBINATINATION  
L5 0 COMBINATINATION

=> s combination

470601 COMBINATION  
110564 COMBINATIONS  
L6 557159 COMBINATION  
(COMBINATION OR COMBINATIONS)

=> s 16 and 11

L7 16 L6 AND L1

=> s 17 not py>2002

4187833 PY>2002  
L8 2 L7 NOT PY>2002

=> d ibib 1-2

L8 ANSWER 1 OF 2 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2001:316848 CAPLUS

DOCUMENT NUMBER: 135:116763

TITLE: The influence of GST-targeted drugs on cell proliferation and stress response

AUTHOR(S): Tew, Kenneth D.

CORPORATE SOURCE: Department of Pharmacology, Fox Chase Cancer Center, Philadelphia, PA, USA

SOURCE: Chemico-Biological Interactions (2001), 133(1-3), 295-300

CODEN: CBINA8; ISSN: 0009-2797

PUBLISHER: Elsevier Science Ireland Ltd.

DOCUMENT TYPE: Journal

LANGUAGE: English

REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2000:466901 CAPLUS

DOCUMENT NUMBER: 133:171845

TITLE: Cellular response to a glutathione S-transferase P1-1 activated prodrug

AUTHOR(S): Rosario, Lilliam A.; O'Brien, Miechelle L.; Henderson, Colin J.; Wolf, C. Roland; Tew, Kenneth D.

CORPORATE SOURCE: Department of Pharmacology, Fox Chase Cancer Center, Philadelphia, PA, USA

SOURCE: Molecular Pharmacology (2000), 58(1), 167-174

CODEN: MOPMA3; ISSN: 0026-895X

PUBLISHER: American Society for Pharmacology and Experimental Therapeutics

DOCUMENT TYPE: Journal

LANGUAGE: English

REFERENCE COUNT: 28 THERE ARE 28 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> d ibib abs kwic 1-2

L8 ANSWER 1 OF 2 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2001:316848 CAPLUS

DOCUMENT NUMBER: 135:116763

TITLE: The influence of GST-targeted drugs on cell proliferation and stress response



AUTHOR(S): Tew, Kenneth D.  
CORPORATE SOURCE: Department of Pharmacology, Fox Chase Cancer Center,  
Philadelphia, PA, USA  
SOURCE: Chemico-Biological Interactions (2001), 133(1-3),  
295-300  
CODEN: CBINA8; ISSN: 0009-2797  
PUBLISHER: Elsevier Science Ireland Ltd.  
DOCUMENT TYPE: Journal  
LANGUAGE: English

AB Novel approaches to target GSTP-1 have produced two new anticancer drugs. A GSTP1-1 activated nitrogen mustard prodrug (TER286) is selectively cytotoxic to tumors, which express high levels of the isoenzyme. Cells transfected with GSTP1-1 are more sensitive to the drug and resistant cells down regulate GSTP1-1 expression. A peptidomimetic inhibitor of GSTP1-1 (TER199) which modulates drug resistance when given in combination with either alkylating agents or natural products also ameliorated drug-induced bone marrow suppressive effects and possessed myeloproliferative activity. This effect is consistent with drug induced dissociation of GSTP1-1 from JNK with resultant downstream proliferative effects.

REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

AB Novel approaches to target GSTP-1 have produced two new anticancer drugs. A GSTP1-1 activated nitrogen mustard prodrug (TER286) is selectively cytotoxic to tumors, which express high levels of the isoenzyme. Cells transfected with GSTP1-1 are more sensitive to the drug and resistant cells down regulate GSTP1-1 expression. A peptidomimetic inhibitor of GSTP1-1 (TER199) which modulates drug resistance when given in combination with either alkylating agents or natural products also ameliorated drug-induced bone marrow suppressive effects and possessed myeloproliferative activity. This effect is consistent with drug induced dissociation of GSTP1-1 from JNK with resultant downstream proliferative effects.

IT 148-82-3, Melphalan 15663-27-1, Cisplatin 25316-40-9, Adriamycin 33069-62-4, Taxol 168682-53-9, TER199 439943-59-6, TER 286  
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(influence of glutathione S-transferase-targeted anticancer drugs on cell proliferation and stress response)

L8 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2000:466901 CAPLUS  
DOCUMENT NUMBER: 133:171845  
TITLE: Cellular response to a glutathione S-transferase P1-1 activated prodrug  
AUTHOR(S): Rosario, Lilliam A.; O'Brien, Michelle L.; Henderson, Colin J.; Wolf, C. Roland; Tew, Kenneth D.  
CORPORATE SOURCE: Department of Pharmacology, Fox Chase Cancer Center, Philadelphia, PA, USA  
SOURCE: Molecular Pharmacology (2000), 58(1), 167-174  
CODEN: MOPMA3; ISSN: 0026-895X  
PUBLISHER: American Society for Pharmacology and Experimental Therapeutics  
DOCUMENT TYPE: Journal  
LANGUAGE: English

AB TER286 [ $\gamma$ -glutamyl- $\alpha$ -amino- $\beta$ (2-ethyl-N,N,N',N'-tetrakis(2-chloroethyl)phosphorodiamidate)-sulfonyl-propionyl-(R)-(-) phenylglycine] is a novel nitrogen mustard prodrug that is preferentially activated by glutathione S-transferase P1-1 (GSTP1-1). A human promyelocytic leukemia /TER286-resistant cell line was selected by chronic, long-term exposure to the prodrug. Although resistance was not readily achieved, eventually a 5-fold resistant clone was isolated. Cross-resistance to melphalan occurred, but not to doxorubicin (Adriamycin), taxol, and  $\gamma$ -glutamyl-S-(benzyl)cysteinyl-R(-)-Ph glycine di-Et ester, a

GSTP1-1 inhibitor. The protein and transcript levels and enzymic activity of GSTP1-1 were reduced significantly in the selected resistant line. GST $\alpha$  levels were unchanged, and GST $\mu$  was undetectable. Although glutathione levels were elevated in human promyelocytic leukemia/TER286 cells, no changes in the expression of thiol-related genes including  $\gamma$ -glutamylcysteine synthetase,  $\gamma$ -glutamyl transpeptidase, or multidrug resistance protein were found. A 7-fold increase in catalase expression in the resistant cell line indicated an adaptive response to oxidative and electrophilic stress, and this was also reflected in the lower prevalence of drug-induced DNA single-strand breaks in the resistant cells. Mouse embryo fibroblast GSTP1-1-/- cells exhibited 2-fold resistance to TER286 compared with GSTP1-1+/+ cells. NIH3T3 cells transfected with combinations of  $\gamma$ -GCS and multidrug resistance protein exhibited enhanced resistance to TER286, although the degree of resistance was impaired by co-transfection of GSTP1-1. These results are consistent with responses in the TER286-resistant cells indicative of GSTP1-1-mediated mechanism of activation. In consequence, these data support the rationale that tumors expressing high levels of GSTP1-1 will be more sensitive to the cytotoxic effects of the drug.

REFERENCE COUNT: 28 THERE ARE 28 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

AB TER286 [ $\gamma$ -glutamyl- $\alpha$ -amino- $\beta$ (2-ethyl-N,N,N',N'-tetrakis(2-chloroethyl)phosphorodiamidate)-sulfonyl-propionyl-(R)-(-) phenylglycine] is a novel nitrogen mustard prodrug that is preferentially activated by glutathione S-transferase P1-1 (GSTP1-1). A human promyelocytic leukemia/TER286-resistant cell line was selected by chronic, long-term exposure to the prodrug. Although resistance was not readily achieved, eventually a 5-fold resistant clone was isolated. Cross-resistance to melphalan occurred, but not to doxorubicin (Adriamycin), taxol, and  $\gamma$ -glutamyl-S-(benzyl)cysteinyl-R(-)-Ph glycine di-Et ester, a GSTP1-1 inhibitor. The protein and transcript levels and enzymic activity of GSTP1-1 were reduced significantly in the selected resistant line. GST $\alpha$  levels were unchanged, and GST $\mu$  was undetectable. Although glutathione levels were elevated in human promyelocytic leukemia/TER286 cells, no changes in the expression of thiol-related genes including  $\gamma$ -glutamylcysteine synthetase,  $\gamma$ -glutamyl transpeptidase, or multidrug resistance protein were found. A 7-fold increase in catalase expression in the resistant cell line indicated an adaptive response to oxidative and electrophilic stress, and this was also reflected in the lower prevalence of drug-induced DNA single-strand breaks in the resistant cells. Mouse embryo fibroblast GSTP1-1-/- cells exhibited 2-fold resistance to TER286 compared with GSTP1-1+/+ cells. NIH3T3 cells transfected with combinations of  $\gamma$ -GCS and multidrug resistance protein exhibited enhanced resistance to TER286, although the degree of resistance was impaired by co-transfection of GSTP1-1. These results are consistent with responses in the TER286-resistant cells indicative of GSTP1-1-mediated mechanism of activation. In consequence, these data support the rationale that tumors expressing high levels of GSTP1-1 will be more sensitive to the cytotoxic effects of the drug.

IT 148-82-3, Melphalan 23214-92-8, Doxorubicin 439943-59-6, TER 286

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(effect of exposure to a glutathione S-transferase P1-1 activated prodrug on antitumor agent resistance of human promyelocytic leukemia cell lines)

=> TER199/cn

TER199 IS NOT A RECOGNIZED COMMAND

The previous command name entered was not recognized by the system. For a list of commands available to you in the current file, enter "HELP COMMANDS" at an arrow prompt (=>).

=> s TER199/cn  
REGISTRY INITIATED  
Substance data SEARCH and crossover from CAS REGISTRY in progress...  
Use DISPLAY HITSTR (or FHITSTR) to directly view retrieved structures.

L10            0 L9

=> s TER 199/cn  
REGISTRY INITIATED  
Substance data SEARCH and crossover from CAS REGISTRY in progress...  
Use DISPLAY HITSTR (or FHITSTR) to directly view retrieved structures.

L12            17 L11

=> s combined or combination  
      460593 COMBINED  
      470601 COMBINATION  
      110564 COMBINATIONS  
      557159 COMBINATION  
          (COMBINATION OR COMBINATIONS)

L13            965782 COMBINED OR COMBINATION

=> s l13 and l12  
L14            4 L13 AND L12

=> d ibib 1-4

L14 ANSWER 1 OF 4 CAPLUS COPYRIGHT 2006 ACS on STN  
ACCESSION NUMBER:        2003:683236 CAPLUS  
DOCUMENT NUMBER:        140:122233  
TITLE:                  Reversal of multiple drug resistance in  
                         cholangiocarcinoma by the glutathione  
                         S-transferase- $\pi$ -specific inhibitor  
                         Ol-hexadecyl- $\gamma$ -glutamyl-S-benzylcysteinyl-D-  
                         phenylglycine Ethylester  
AUTHOR(S):              Nakajima, Takaharu; Takayama, Tetsuji; Miyanishi,  
                         Koji; Nobuoka, Atsushi; Hayashi, Tsuyoshi; Abe,  
                         Tomoyuki; Kato, Junji; Sakon, Kiyoyuki; Naniwa,  
                         Yoshimitsu; Tanabe, Hirohumi; Niitsu, Yoshiro  
CORPORATE SOURCE:        Fourth Department of Internal Medicine, Sapporo  
                         Medical University School of Medicine, Sapporo, Japan  
SOURCE:                  Journal of Pharmacology and Experimental Therapeutics  
                         (2003), 306(3), 861-869  
                         CODEN: JPETAB; ISSN: 0022-3565  
PUBLISHER:              American Society for Pharmacology and Experimental  
                         Therapeutics  
DOCUMENT TYPE:           Journal  
LANGUAGE:                English  
REFERENCE COUNT:        35        THERE ARE 35 CITED REFERENCES AVAILABLE FOR THIS  
                         RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L14 ANSWER 2 OF 4 CAPLUS COPYRIGHT 2006 ACS on STN  
ACCESSION NUMBER:        2003:414079 CAPLUS

DOCUMENT NUMBER: 138:406943  
 TITLE: Pharmaceutical compositions containing glutathione analogs  
 INVENTOR(S): Kauvar, Lawrence M.; Lum, Robert T.; Lyttle, Matthew H.; Macsata, Robert W.; Schow, Steven R.; Villar, Hugo O.; Kozlowski, Michael R.  
 PATENT ASSIGNEE(S): USA  
 SOURCE: U.S. Pat. Appl. Publ., 16 pp.  
 CODEN: USXXCO  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2003100511	A1	20030529	US 2001-903442	20010710
US 7029695	B2	20060418		

PRIORITY APPLN. INFO.: US 2001-903442 20010710  
 OTHER SOURCE(S): MARPAT 138:406943  
 REFERENCE COUNT: 17 THERE ARE 17 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L14 ANSWER 3 OF 4 CAPLUS COPYRIGHT 2006 ACS on STN  
 ACCESSION NUMBER: 2003:364945 CAPLUS  
 DOCUMENT NUMBER: 139:207702  
 TITLE: Resistance to phorbol 12-myristate 13-acetate-induced cell growth arrest in an HL60 cell line chronically exposed to a glutathione S-transferase  $\pi$  inhibitor  
 AUTHOR(S): Gate, Laurent; Lunk, Alexandra; Tew, Kenneth D.  
 CORPORATE SOURCE: Department of Pharmacology, Fox Chase Cancer Center, Philadelphia, PA, 19111, USA  
 SOURCE: Biochemical Pharmacology (2003), 65(10), 1611-1622  
 CODEN: BCPA6; ISSN: 0006-2952  
 PUBLISHER: Elsevier Science Inc.  
 DOCUMENT TYPE: Journal  
 LANGUAGE: English  
 REFERENCE COUNT: 23 THERE ARE 23 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L14 ANSWER 4 OF 4 CAPLUS COPYRIGHT 2006 ACS on STN  
 ACCESSION NUMBER: 2001:316848 CAPLUS  
 DOCUMENT NUMBER: 135:116763  
 TITLE: The influence of GST-targeted drugs on cell proliferation and stress response  
 AUTHOR(S): Tew, Kenneth D.  
 CORPORATE SOURCE: Department of Pharmacology, Fox Chase Cancer Center, Philadelphia, PA, USA  
 SOURCE: Chemico-Biological Interactions (2001), 133(1-3), 295-300  
 CODEN: CBINA8; ISSN: 0009-2797  
 PUBLISHER: Elsevier Science Ireland Ltd.  
 DOCUMENT TYPE: Journal  
 LANGUAGE: English  
 REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> d kwic 2

L14 ANSWER 2 OF 4 CAPLUS COPYRIGHT 2006 ACS on STN  
 AB . . . hematopoiesis, protect hematopoietic cells from damage caused by radiation or chemotherapy, or potentiate the stimulatory action of one or a combination of cytokines on colony formation by hematopoietic progenitor cells, protect a subject from a destructive effect of a